Donoghue Forlines’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-23,126
| Closed | -$3.22M | – | 136 |
|
|
2026
Q1 | $3.22M | Buy |
+23,126
| New | +$3.24M | 0.89% | 22 |
|
|
2025
Q2 | – | Sell |
-19,758
| Closed | -$2.21M | – | 114 |
|
|
2025
Q1 | $2.21M | Sell |
19,758
-20,196
| -51% | -$2.08M | 0.7% | 48 |
|
|
2024
Q4 | $3.69M | Buy |
39,954
+13,524
| +51% | +$1.22M | 1.23% | 6 |
|
|
2024
Q3 | $2.22M | Buy |
26,430
+6,357
| +32% | +$485K | 0.63% | 31 |
|
|
2024
Q2 | $1.38M | Buy |
20,073
+2,309
| +13% | +$154K | 0.39% | 71 |
|
|
2024
Q1 | $1.3M | Buy |
17,764
+3,229
| +22% | +$248K | 0.37% | 81 |
|
|
2023
Q4 | $1.18M | Sell |
14,535
-19,949
| -58% | -$1.55M | 0.37% | 80 |
|
|
2023
Q3 | $2.58M | Buy |
34,484
+6,151
| +22% | +$473K | 0.92% | 16 |
|
|
2023
Q2 | $2.18M | Buy |
28,333
+2,227
| +9% | +$178K | 0.68% | 23 |
|
|
2023
Q1 | $2.17M | Sell |
26,106
-5,455
| -17% | -$452K | 0.78% | 16 |
|
|
2022
Q4 | $2.71M | Buy |
31,561
+17,022
| +117% | +$1.35M | 0.96% | 16 |
|
|
2022
Q3 | $897K | Sell |
14,539
-12,808
| -47% | -$808K | 0.32% | 43 |
|
|
2022
Q2 | $1.69M | Sell |
27,347
-14,415
| -35% | -$892K | 0.44% | 32 |
|
|
2022
Q1 | $2.48M | Buy |
41,762
+9,573
| +30% | +$612K | 0.54% | 31 |
|
|
2021
Q4 | $2.34M | Sell |
32,189
-2,245
| -7% | -$155K | 0.4% | 45 |
|
|
2021
Q3 | $2.4M | Buy |
34,434
+14,845
| +76% | +$1.04M | 0.47% | 46 |
|
|
2021
Q2 | $1.35M | Buy |
19,589
+268
| +1% | +$17.9K | 0.25% | 92 |
|
|
2021
Q1 | $1.25M | Sell |
19,321
-18,853
| -49% | -$1.22M | 0.24% | 106 |
|
|
2020
Q4 | $2.22M | Buy |
+38,174
| New | +$2.3M | 0.43% | 36 |
|
|
2019
Q4 | – | Sell |
-65,953
| Closed | -$4.18M | – | 171 |
|
|
2019
Q3 | $4.18M | Sell |
65,953
-30,722
| -32% | -$2.01M | 0.6% | 59 |
|
|
2019
Q2 | $6.53M | Buy |
+96,675
| New | +$6.36M | 0.76% | 47 |
|
|
2018
Q4 | – | Sell |
-183,324
| Closed | -$14.2M | – | 78 |
|
|
2018
Q3 | $14.2M | Sell |
183,324
-42,799
| -19% | -$3.23M | 1.1% | 21 |
|
|
2018
Q2 | $16M | Buy |
226,123
+4,424
| +2% | +$312K | 1.32% | 32 |
|
|
2018
Q1 | $16.7M | Sell |
221,699
-15,000
| -6% | -$1.19M | 1.45% | 38 |
|
|
2017
Q4 | $17M | Buy |
236,699
+209,486
| +770% | +$15.9M | 1.28% | 51 |
|
|
2017
Q3 | $2.21M | Buy |
+27,213
| New | +$2.08M | 0.23% | 79 |
|
Other funds holding GILD
Donoghue Forlines's GILD Position: Q2 2026 in Review
Donoghue Forlines sold out of Gilead Sciences (GILD) in Q2 2026, closing a stake of 23,126 shares — an estimated $3.22M sold.
Donoghue Forlines first reported a position in GILD in Q3 2017 and held it in 26 quarters. The position peaked at $17M in Q4 2017. 2,283 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Donoghue Forlines reported no remaining Gilead Sciences position as of Q2 2026 after selling out during the quarter.
- Donoghue Forlines sold 23,126 Gilead Sciences shares in Q2 2026, an estimated $3.22M.
- Donoghue Forlines first reported a position in Gilead Sciences in Q3 2017 and held it in 26 quarters.
- Donoghue Forlines's Gilead Sciences position peaked at $17M in Q4 2017.
- 2,283 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Donoghue Forlines's 13F filing for Q2 2026, filed 7 Aug 2026.